News25/Ratings12
News · 26 weeks81+100%
2026-03-012026-08-23
Mix1690d
- SEC Filings6(38%)
- Other3(19%)
- Earnings3(19%)
- Analyst2(13%)
- Insider2(13%)
Latest news
25 items- INSIDERSEC Form 4 filed by SVP, Controller & CAO Zieselman Neil Craig4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zieselman Neil Craig3 - Solventum Corp (0001964738) (Issuer)
- PRThe GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForRENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to address. On August 3, 2026, Conexeu Sciences Inc. (NASDAQ:CNXU) President and Chief Executive Officer Miles Harrison sat down with IPO Edge for a fireside chat that put that
- SECSEC Form 10-Q filed by Solventum Corporation10-Q - Solventum Corp (0001964738) (Filer)
- SECSolventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Solventum Corp (0001964738) (Filer)
- PRSolventum Reports Second Quarter 2026 Financial ResultsReported sales increased 2.2%; organic sales increased 9.5%Announces intent to separate its Health Information Systems business segmentIncreases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flowEAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 HighlightsSales of $2.2 billion, increased 2.2% on a reported basis; an increase of 9.5% on an organic basisGAAP diluted earnings per share of $0.53; adjusted diluted earnings per share of $2.55, a 50.9% increaseOperating cash flow of $227 million
- SECSolventum Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Solventum Corp (0001964738) (Filer)
- PRSolventum Announces Intent to Separate its Health Information Systems BusinessStrengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase transformation strategyPositions Health Information Systems, a leading, scaled, healthcare software business, to accelerate its strategic vision and growth agenda as a separate entityUnlocks shareholder value and enables targeted investment supporting innovation and growth across both businessesEAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced its intention to pursue a separation of its Health Information Systems business as part of the company's ongoing portfolio optimization strategy. The company will evaluate a range of separation pathways with the objective of max
- ANALYSTSolventum upgraded by UBS with a new price targetUBS upgraded Solventum from Neutral to Buy and set a new price target of $95.00
- SECSolventum Corporation filed SEC Form 8-K: Leadership Update8-K - Solventum Corp (0001964738) (Filer)
- PRSolventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Wednesday, August 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:6342275A replay of the webcast, the earnings
- ANALYSTBMO Capital Markets initiated coverage on Solventum with a new price targetBMO Capital Markets initiated coverage of Solventum with a rating of Market Perform and set a new price target of $81.00
- SECSolventum Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Solventum Corp (0001964738) (Filer)
- SECSEC Form SD filed by Solventum CorporationSD - Solventum Corp (0001964738) (Filer)
- SECSolventum Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Solventum Corp (0001964738) (Filer)
- PRSolventum to Participate in the 2026 Jefferies Healthcare ConferenceEAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m. EDT in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pion
- SECSolventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Solventum Corp (0001964738) (Filer)
- INSIDERSEC Form 4 filed by Director Alban Carlos4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Cox Carrie Smith4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Devore Susan D.4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Edwards Shirley Ann4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Eisenberg Glenn A4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Harris Bernard A Jr4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director May Karen J4 - Solventum Corp (0001964738) (Issuer)
- INSIDERSEC Form 4 filed by Director Mily Elizabeth4 - Solventum Corp (0001964738) (Issuer)
SOLV FAQ
6 questionsWhere does SOLV stock trade?
Solventum Corporation (SOLV) is listed on NYSE.What sector and industry is SOLV in?
Solventum Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Solventum Corporation go public?
Solventum Corporation (SOLV) completed its IPO in 2024.What are analysts saying about SOLV?
Solventum Corporation has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-07-28.What companies are similar to SOLV?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SOLV side-by-side with any of them on Quantisnow.How can I track SOLV on Quantisnow?
Quantisnow aggregates Solventum Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOLV to receive live email and push alerts on every new disclosure.